Fecha de publicación: 15/01/2025 Fuente: FierceBiotech Neumora Therapeutics’ phase 3 fail was worse than analysts feared. The biotech provided a closer look at the data Tuesday, shutting down one source of hope that analysts had clung to after the initial blow.